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Objectives Quantitative Fluorescent PCR (QF-PCR) is a simpler and faster method of detecting common
chromosomal abnormalities when compared to cytogenetic analysis. The aim of our study is to investigate
the applicability of this methodology in a population where consanguineous marriages are common and to
estimate the heterozygous frequency of the PCR markers used.
Methods Four hundred and twenty-three DNA samples were extracted from uncultured amniocytes and
amplified with 18 short tandem repeats (STR) markers specific to chromosomes 13, 18 and 21. Amplification
products were analyzed using the GeneScan software.
Results QF-PCR correctly identified all the numerical abnormalities related to chromosomes 13, 18 and 21.
A total of 24 autosomal trisomies (5.7%) were detected. The markers D21S1432 and D21S11 were the most
consistent in providing unequivocal positive results for chromosome 21 and the heterozygosity percentages of
the markers used were lower than the values reported in Western populations.
Conclusion QF-PCR is reliable for the prenatal diagnosis of numerical anomalies of the chromosomes 13,
18 and 21 in our study population. The absence of STR heterozygosity data from Lebanon and surrounding
countries makes our study very useful for the development of a reliable QF-PCR trisomy detection test.
Copyright  2006 John Wiley & Sons, Ltd.
KEY WORDS: aneuploidy; trisomy; QF-PCR
INTRODUCTION
Common autosomal trisomies affect 1 in 400 new-
borns annually (De Vigan et al., 2001). The most com-
mon among these trisomies is Down syndrome (DS),
affecting 1 : 600 newborns. Currently, the triple test,
which includes alphafetoprotein (AFP), human chori-
onic gonadotrophin (hCG) and unconjugated estriol,
is an accepted screening test for autosomal trisomies
(Palomaki et al., 1997). This test is usually performed
between the 15th and 18th week of gestation and detects
62% of the DS cases (Wald et al., 2003). An increased
nuchal translucency on ultrasound (Snijders et al., 1998)
has been shown as an early indicator of DS. Recently,
the quadruple test made by adding the inhibin A marker
to the triple test was shown to detect 75% of DS cases
and ought to be the standard screening test for DS (Wald
et al., 2003). The serum integrated test adds a serum test
for PAPP-A in the first trimester and to the quadruple test
in the second trimester. This test reportedly detects 94%
of DS cases (Wald and Hackshaw, 2000). When any of
the above diagnostic tools is positive, a confirmatory test
is warranted. Over the last 30 years, cytogenetic kary-
otyping on amniotic fluid has been the traditional method
used for this purpose. Although very accurate and still
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widely used, karyotyping requires highly skilled per-
sonnel, culture of amniocytes or other tissue cells, and
results in increased costs. Other accepted weaknesses of
karyotyping have been the possibility of culture failure
or overgrowth of maternal cells (Winsor et al., 1996), as
well as the delay between the amniocentesis and results
of the karyotyping. This delay has been presumed to
result in significant maternal anxiety. As an alterna-
tive method, fluorescence in situ hybridization (FISH)
was introduced in the 1980s. By using fluorescent tags
labeled ssDNA probes, FISH can localize chromosome
abnormalities at the metaphase and interphase stages of
mitotic division. It has therefore the advantage of being
performed on nondividing cells, eliminating therefore
the need for cell culture. However, this technique cannot
be automated, shows diffuse signals when the interphase
nuclei are examined, and has higher levels of noninfor-
mativeness at late gestational age (Pertl et al., 1997). In
addition, the cost effectiveness of this test has been ques-
tioned (Eiben et al., 1999). A more recent approach is
the amplification of short tandem repeats (STR) on chro-
mosome 13, 18 and 21 using polymerase chain reaction
(PCR), followed by the analysis of fluorescent inten-
sity to test for the presence of a potential additional
allele on an extranumerary chromosome. This method
was first applied to X chromosome aneuploidy in 1991
(Lubin et al., 1991), then to autosomal aneuploidies in
the early 1990s (Mansfield, 1993; Pertl et al., 1994),
and was later confirmed by larger studies (Mann et al.,
2001; Bili et al., 2002; Voglino et al., 2002). It has the
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potential to be automated, can be performed on uncul-
tured cells, and yields a rapid diagnosis, hence reducing
maternal anxiety. It is also fairly operator-independent
when the appropriate settings are used.
Inherent to this technique is the use of fluorescent
markers whose informativeness is directly proportional
to the heterozygosity of the alleles amplified. Hence,
the use of the same markers for other populations is not
evident. A recent study on a large number of samples
indicates that PCR can be considered as a stand-alone
screening test, with minimal chances of not diagnosing
the common chromosomal abnormalities (Nicolini et al.,
2004). Until now, no current data is available from the
Middle Eastern populations on the use of this method for
prenatal diagnosis. These populations are characterized
by a higher rate of consanguinity, leading to less allelic
variation when compared to the Western communities.
We have therefore aimed at verifying the extent to which
the use of this technique is justified in our population.
MATERIAL AND METHODS
Samples
Four hundred and twenty-three amniotic fluid samples
were received at our center for analysis. The main
indications for amniocentesis included advanced mater-
nal age (>35 years; 33%), abnormal ultrasound results
(22%), abnormal maternal triple screen (22%), which is
the only trisomy screening test provided in the country,
maternal anxiety (4%), previous pregnancy with trisomy
(3%) and others (16%). Amniocentesis was performed
between 14 and 16 weeks of gestation for most sam-
ples with a few exceptions of late gestational age. Three
samples were excluded from the study due to severe
maternal blood contamination. Karyotype results when
available were obtained from patients after conventional
cytogenetic analyses were performed at the American
University of Beirut Medical Center.
DNA preparation
Duplicates of 1.5 mL of each amniotic fluid were
spun down at 10 000 rpm for 5 min. The pellet
was subsequently washed with 150 µL of 1x PBS.
After an additional centrifugation, the pellet was
resuspended in 150 µL of cell lysis buffer (10 mM
Tris-Cl pH 8.0–5 mM ethylenediaminetetra-acetic acid
(EDTA)–400 mM NaCl), 5 µL of 10% sodium dodecyl
sulfate and 4 µL of proteinase K (20 mg/mL) and
then incubated at 55 ◦C for 2 h. After incubation,
55 µL of 5.5 M NaCl was added and the sample was
vigorously vortexed and then centrifuged for 15 min at
13 000 rpm. The supernatant was then transferred into a
fresh tube containing 600 µL of 99% ethanol. The tube
was gently shaken and then centrifuged for 10 min at
13 000 rpm. The ethanol was discarded, and the pellet
was washed with 200 µL of 70% ethanol; the tube was
then centrifuged for 5 min at 13 000 rpm and the ethanol
was aspirated. The DNA pellet was air dried and then
resuspended in 20 µL of Tris-EDTA buffer (10 mM Tris-
Cl, pH 8.0, 1 mM EDTA). The DNA concentration was
determined by spectrophotometry.
PCR amplification
Five chromosome specific primer sets were used in two
separate reactions to amplify STR markers on chro-
mosome 13 and 18. D18S535, D13S796, D13S631,
D13S258 and D18S851 markers were used in the first
reaction and D18S536, D18S976, D13S325, D13S788
and D18S51 were used in the second. In a third reac-
tion, eight chromosome specific STR markers were used
to amplify STR markers on chromosome 21. The primer
sequences used in the amplification reactions are listed
in Table 1. PCR was carried out in 10 µL reactions
containing 0.3 µM of each primer, 0.25 mM dNTPs,
2 mM MgCl2, 0.5 units of AmpliTaq Gold polymerase
(Applied Biosystems, Foster City, CA) and 30 ng of
genomic DNA, in 1x PCR Buffer II (Applied Biosys-
tems). The enzyme was activated at 95 ◦C for 12 min
before 30 cycles of amplification in a GeneAmp 9700
PCR system (Applied Biosystems). Each amplification
cycle consisted of a 94 ◦C denaturation step for 30 s, an
annealing step at 55 ◦C for 30 s and a 1 min extension
at 72 ◦C. Finally, an extension step at 72 ◦C for 7 min
was performed.
Capillary electrophoresis
One microliter of the PCR reaction mixture was then
mixed with 11 µL of deionized formamide and 0.5 µL
of the internal size standard GS-500 TAMRA (Applied
Biosystems). The mixture was then denatured at 95 ◦C
for 5 min and chilled on ice before loading on the
ABI 310 Genetic Analyzer (Applied Biosystems). Cap-
illary electrophoresis was performed using POP-4 poly-
mer (Applied Biosystems). Electrophoresis analysis was
performed using the GeneScan analysis 2.1software
(Applied Biosystems), the products were quantified as
peaks corresponding to the relative amount of PCR yield
for different allelic lengths at a specific chromosome site
identified by the marker.
RESULTS
Four hundred and sixteen samples (98%) were clear with
no evidence of macroscopic blood contamination, four
samples (1%) were mildly bloodstained, and three (1%)
were severely bloodstained and were removed from the
study. The mildly stained samples revealed fetal peaks
that were clearly distinguished from the small maternal
blood–contaminating peaks. The contaminating peaks
were neither equal in size nor did they show a character-
istic 2 : 1 ratio. This confirms previous reports showing
that mild contamination does not appear to reduce the
usefulness of the PCR diagnosis (Schmidt et al., 2000).
Maternal blood contamination is reported to occur in
∼1% of cases with mild variation depending on the
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Table 1—Sequence and location of the STR primers used in this study
Marker Sequence Location
Size of PCR
product Label
D21S11 TAT-GTC-AGT-CAA-TTC-CCC-AAG-TGA (F) 21q11.1 216–244 TET
AAT-GTG-TGT-CCT-TCC-AGG-C (R)
D21S1411 ATG-ATG-AAT-GCA-TAG-ATG-GAT-G (F) 21q22.3 279–303 TET
AAT-GTG-TGT-CCT-TCC-AGG-C (R)
D21S1412 CGG-AGG-TTG-CAC-TGA-GTT-G (F) 21q22.13 393–429 HEX
GGG-AAG-GCT-ATG-GAG-GAG-A (R)
D21S1432 CTT-AGA-GGG-ACA-GAA-CTA-ATA-GGC (F) 21p11.2 128–144 FAM
AGC-CTA-TTG-TGG-GTT-TGT-GA (R)
D21S1435 CCC-TCT-CAA-TTG-TTT-GTC-TAC-C (F) 21q21.1 161–181 HEX
GCA-AGA-GAT-TTC-AGT-GCC-AT (R)
D21S1440 GAG-TTT-GAA-AAT-AAA-GTG-TTC-TGC (F) 21q22.12 150–166 TET
CCC-CAC-CCC-TTT-TAG-TTT-TA (R)
D21S1270 CTA-TCC-CAC-TGT-ATT-ATT-CAG-GGC (F) 21q21.2 175–195 FAM
TGA-GTC-TCC-AGG-TTG-CAG-GTG-ACA (R)
IFNAR TTA-CGT-TCT-TCA-TTT-GAT-CTT-AGC-C (F) 21q22.1 232–254 FAM
(D21S2039) CCA-GGC-ATG-ATG-GCA-CAC (R)
D13S631 GGC-AAC-AAG-AGC-AAA-ACT-CT (F) 13q32.1 197–209 TET
TAG-CCC-TCA-CCA-TGA-TTG-G (R)
D13S788 GAT-TGA-GGT-AGG-GTC-CCA-AG (F) 13q14.11 250–270 TET
GCT-CCA-TAA-TTG-TGT-GAG-CC (R)
D13S796 CAT-GGA-TGC-AGA-ATT-CAC-AG (F) 13q33.2 147–167 FAM
TCA-TCT-CCC-TGT-TTG-GTA-GC (R)
D13S325 TCC-TTT-AAG-TGT-CTA-GAG-AGG-AGG (F) 13q13.3 205–221 FAM
TCT-CTC-TCA-GAA-GTT-TGG-AAG-C (R)
D13S258 ACC-TGC-CAA-ATT-TTA-CCA-GC (F) 13q21.32 236–284 HEX
GAC-AGA-GAG-AGG-GAA-TAA-ACC (R)
D18S51 GAG-CCA-TGT-TCA-TGC-CAC-TG (F) 18q21.32 267–311 HEX
CAA-ACC-CGA-CTA-CCA-GCA-AC (R)
D18S535 TCA-TGT-GAC-AAA-AGC-CAC-AC (F) 18q12.2 130–154 HEX
AGA-CAG-AAA-TAT-AGA-TGA-GAA-TGC-A (R)
D18S536 ATT-ATC-ACT-GGT-GTT-AGT-CCT-CTG (F) 18q11.2 141–173 TET
CAC-AGT-TGT-GTG-AGC-CAG-TC (R)
D18S851 CTG-TCC-TCT-AGG-CTC-ATT-TAG-C (F) 18q21.1 250–278 FAM
TTA-TGA-AGC-AGT-GAT-GCC-AA (R)
D18S976 GGA-CTT-CTC-TGC-TGC-CAT-AA (F) 18q11.31 165–189 HEX
CTC-CCT-GAT-TTT-TAG-CTG-GG (R)
FAM, 6-carboxyfluorescein; TET, Tetrachloro-6-carboxyfluorescein; HEX, Hexachloro-6-carboxyfluorescein.
technique used (Steed et al., 2002). Contamination by
maternal cells is however reported to affect the efficiency
of aneuploidy detection by FISH (Bryndorf et al., 1997).
Three amniotic fluid samples (0.7%) failed to grow in
the cytogenetic laboratory and no karyotype results were
obtained for these samples. These samples were nega-
tive by PCR for autosomal trisomies, and the results
were confirmed after the delivery of normal babies.
In the GeneScan analysis, we adhered to the guide-
lines set at the Austrian symposium in 2001, whereby
normal samples were defined as those that show two
peaks with area ratios of the shorter and longer allele
within the range 0.8–1.4. Trisomic samples were defined
as samples with diallelic pattern on GeneScan analysis
with ratios of the alleles of <0.65 or >1.8, or samples
showing a triallelic pattern with a ratio of 1 : 1 : 1. In our
analysis, we considered the ratio of the longer to shorter
peak. Samples with ratios of the allele peaks greater than
4 were retested. Samples that showed peak area ratios
between 1.40 and 1.80 were considered noninformative.
Comparison of the PCR analysis with the kary-
otype results revealed that quantitative fluorescent PCR
(QF-PCR) correctly identified all the numerical abnor-
malities related to chromosomes 13, 18 and 21. A total
of 24 autosomal trisomies (5.7%) were detected in our
study group. In 396 cases, the chromosome-amplified
STR markers showed either two peaks with similar
area ratios or one noninformative homozygous peak
(Figure 1(a)). These samples were predicted to be nor-
mal, and these results were confirmed later by cytoge-
netic analysis or after the delivery of normal babies.
Among the 24 samples identified as autosomal trisomy
cases, 20 samples were diagnosed as DS (trisomy 21),
3 samples as Edwards syndrome (trisomy 18) and 1
sample as Patau syndrome (trisomy 13). These cases
showed either three distinctive STR peaks with similar
peak areas (Figure 1(b)), consistent with three different
alleles, or two peaks with ratios of >1.8 (Figure 1(c)).
The allele peak ratios seen with trisomy 21 cases are
shown in Table 2. In this study, no sample was non-
informative when all the markers were used. When
compared to the karyotyping results, none of the ampli-
fied samples was found to be false positive or false
negative.
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Table 2—The allelic patterns of the STR markers used in the diagnosis of the 20 trisomy 21 cases in the study
D21S11 D21S1270 D21S1411 D21S1412 D21S1432 D21S1435 IFNAR D21S1440
Diallelic 9 10 8 7 13 10 8 12
Triallelic 10 6 6 9 7 5 8 5
Noninformativea 1 4 6 1 0 5 4 3
Rangeb 1.82–2.45 2.05–2.95 2.05–2.42 1.84–2.69 1.81–2.52 1.82–2.43 2.65–3.41 1.82–2.57
Meanc 2.11 ± 0.25 2.52 ± 0.45 2.25 ± 0.19 2.03 ± 0.52 2.08 ± 0.25 2.01 ± 0.21 3.04 ± 0.54 2.13 ± 0.39
a Having one allele (homozygous) or two alleles with a peak ratio between 1.4 and 1.8.
b Lowest and highest peak ratios.
c Mean average of peak ratios.
(a) Normal fetus 
(b) Down’s syndrome
(c) Down’s syndrome 
Figure 1—Peak heights of the amplified D21S1432 marker. (a) A
normal result showing equal intensity of the peaks. (b) Fetus with DS
showing three peaks of equal intensities. (c) Fetus with DS showing
two peaks with a ratio of 2 : 1
Two of the STR markers used, IFNAR and D21S1411,
showed the highest percentage of heterozygosity for
chromosome 21 (Table 3). D18S51 and D13S796 mark-
ers showed the highest percentage of heterozygosity for
chromosomes 18 and 13 respectively.
D21S1432 and D21S11 were the most consistent in
providing unequivocal positive results (Table 2). The
D21S11 marker detected all the trisomic samples, and
D21S1432 had one noninformative result (ratio of 1.6).
However, these two markers showed a relatively low
percentage of heterozygosity when all the samples were
considered (Table 3).
DISCUSSION
A central concern when using QF-PCR in prenatal
diagnosis is determining the appropriate set and number
of STR markers to be used for amplification. An ideal
diagnostic test would include few STR primers that
detect the largest number of chromosomal irregularities.
Table 3—STR heterozygosity comparisons between the study and other
populations
Heterozygous percentage
Markers
Lebanese
population
(%)
Western countries
(Hulten et al., 2003)
(%)
Greek populationa
(Bili et al., 2002)
(%)
D21S11 78.9 90 77
D21S1411 89.1 93 83
D21S1412 82.8 85 —
D21S1432 78.8 — —
D21S1435 77.0 79 —
D21S1440 80.6 — —
D21S1270 72.7 86 —
IFNAR 83.3 83 —
D13S631 78.9 83 83
D13S788 79.7 — —
D13S796 81.6 — —
D13S325 76.5 — —
D13S258 76.8 83 85
D18S51 85.6 93 83
D18S535 80.2 92 77
D18S536 76.7 — —
D18S851 78.5 — —
D18S976 82.8 — —
a The Greek population was used for comparison because of its geographic vicinity.
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Establishing proper diagnosis should require a minimum
of two informative markers per chromosome.
The QF-PCR analysis can detect both trisomy 21
and unbalanced Robertsonian translocations causing DS.
To discriminate between the two categories, the use of
markers specific to the short arm of chromosome 21
is warranted. This distinction is of significant clinical
importance given the role of genetic counseling for the
parents in the case of Robertsonian translocation–related
DS. In our study, we used a short arm specific marker,
D21S1432, and no DS secondary to translocation was
detected.
Compared to FISH, which has also been used on
uncultured amniocytes, QF-PCR offers several advan-
tages. It is a less expensive technique and can be eas-
ily automated (Verma et al., 1998), whereas FISH is a
lengthy and arduous method. FISH has been reported
to yield a high percentage of noninformative results
when performed at a late gestational age, which might
be explained by an insufficient number of cells or an
increased degradation of the chromatin at more than
28 weeks of gestation (Pertl et al., 1999). QF-PCR can
be performed at all gestational ages with accuracy (Pertl
et al., 1999). Both techniques are however limited by the
fact that mosaic samples are hard to diagnose efficiently
and accurately.
The present study investigates the efficiency of new as
well as established STR markers in the prenatal detection
of three autosomal aneuploidies, in an attempt to deter-
mine the optimal selection of STR markers in a non-
Western population with a high degree of homogeneity
resulting from a high percentage of consanguineous mar-
riages. The QF-PCR method has been shown to detect
chromosome aneuploidy accurately in prenatal samples
(Pertl et al., 1994, 1997, 1999; Verma et al., 1998; Lev-
ett et al., 2001), and has been implemented recently as a
diagnostic tool in several centers worldwide. QF-PCR is
informative when the parental sequences amplified dif-
fer in size and the variability of the alleles depends on
the natural variation in the population studied (Verma
et al., 1998). The advantage provided by a particular
marker depends mainly on the heterozygosity of the alle-
les amplified in the studied population.
In our study, a total of 18 STR markers were used.
The use of such a large number of markers was justified
by the lack of information about the true percentage of
STR heterozygosity in the population studied.
For cost effectiveness, it has been widely accepted
that initial work-up should be started with the use
of two markers, with progressive addition of markers.
Owing to the high incidence of trisomy 21, we will
focus on a possible algorithm for detection of this
trisomy using QF-PCR in our study population. Since
this test is a diagnostic tool, the markers with the
highest sensitivity should be used initially. Our results
indicate that D21S11 and D21S1432 when present in
the heterozygous form were the most consistent in
clearly determining a trisomy and should be used in
the initial step of the test. However, because of the low
percentage of heterozygosity of these two markers in our
population, only 68% of the samples were informative
when results from both markers were considered and
31% of the cases were informative for either one of the
two markers. When the highly polymorphic D21S1411
was used as the third consecutive marker, the overall
trisomy 21 informativeness rate for all three markers
was 95.4%. Finally, with the addition of D21S1412 all
tested samples were informative and the QF-PCR results
were 100% concordant with the karyotype results data.
Figure 2 presents a potential algorithm that can be used
for the effective detection of DS in a population similar
to the one used for this study. Although the two markers
used in the initial step are not very polymorphic in our
population, they are very reliable in detecting all trisomy
cases and the use of two additional highly polymorphic
markers increased the trisomy detection to 100%.
We compared our data with data obtained from a study
that was done on a Greek population (Bili et al., 2002).
The Greek population was chosen because of the lack of
data from neighboring countries, and because of its geo-
graphic proximity (although not necessarily genetically
related) to the population under study. When compared
to the percentages of heterozygosity in the literature,
our results show lower values (Table 3) (Hulten et al.,
2003). Since the polymorphism of the markers used is
population-dependent, this difference can be explained
by the difference in the allele pool in the population stud-
ied. In addition, Middle Eastern countries are character-
ized by higher rates of consanguinity. The population we
studied displays a high percentage of consanguineous
marriages, estimated around 25% (UNICEF, 2000), of
which 15% are 1st degree cousin marriages and 10% are
distant relative marriages. In Western countries where
consanguinity is low, a large percentage of the popu-
lation tends to display a heterozygous genotype. These
facts and the absence of STR heterozygosity data from
Lebanon and surrounding countries make our study very
Figure 2—Suggested algorithm for DS detection
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useful for the development of a reliable QF-PCR trisomy
detection test.
The QF-PCR test permits accurate and reliable identi-
fication of specific numerical anomalies within 24 h after
amniocentesis as compared to an average of 15 days
with the traditional cytogenetic analysis. Providing a
quick and reliable diagnosis for common autosomal
aberrations is of major clinical importance especially in
the context of high-risk pregnancies that are close to the
widely acceptable limits of termination of pregnancy or
at a late gestational age. In addition, it requires smaller
samples for analysis, 1.5 mL was used in our study.
A decision to recommend universal screening for
autosomal trisomies has not been made yet (Petrou
and Mugford, 2004), however, QF-PCR is an attractive
screening option since it can be easily automated and
has been shown to be a cost-effective technique when
compared to all other screening methods.
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